First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein e (CENP-E), in patients with refractory cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 733-741

  Chung, Vincent ^a   Heath, Elisabeth I ^b   Schelman, William R ^c   Johnson, Brendan M ^d   Kirby, Lyndon C ^d   Lynch, Kerlin M ^d   Botbyl, Jeffrey D ^e   Lampkin, Thomas A ^d   Holen, Kyle D ^c  

^a City of Hope Medical Center   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d GLAXOSMITHKLINE   (United States)

^e Provonix Inc   (United States)

Author keywords

Antimitotic; Cancer; CENP E; Pharmacokinetics

Indexed keywords

BCG VACCINE; CARBOPLATIN; CENTROMERE PROTEIN E; GEMCITABINE; GSK 923295; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOCYTE COUNT; LIVER CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROURETERECTOMY; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; REFRACTORY SOLID TUMOR; SIDE EFFECT; SINUS TACHYCARDIA; SOLID TUMOR; STOMACH CANCER; TACHYCARDIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIMITOTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHROMOSOMAL PROTEINS, NON-HISTONE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SARCOSINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859744596     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1756-z     Document Type: Article

References (20)

1. Milagrese MR, Carlson RO (2006) Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15:1411-1425
2. Wood KW, Lad L, Luo L, Qian X et al (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. PNAS 107(13):5839-5844
3. Yu U, Feng Y-M (2010) The role of kinesin family proteins in tumorigenesis and progression. Cancer 116:5150-5160
4. Wacker SA, Kapoor TM (2010) Targeting a kinetochore-associated motor protein to kill cancer cells. PNAS 107(13):5699-5700
5. Weaver BAA, Cleveland DW (2007) Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67:10103-10105 (Pubitemid 350070779)
6. Sutton D, Gilmartin AG et al (2007) A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro. GlaxoSmithKline, Collegeville, PA, Cytokinetics, South[abstract]. In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007; San Francisco, CA. AACR Meeting Abstracts, Oct 2007; Philadelphia (PA) p 100 Abstract A111
7. Chua PR, Radhika R, Desai et al (2007), DiVerential response of tumor cell lines to inhibition of the mitotic checkpoint regulator and mitotic kinesin, CENP-E. [abstract]. In: AACR Meeting abstracts,-NCI-EORTC International conference: molecular targets and cancer therapeutics; 22-26 Oct 2007; San Francisco (CA) Abstract A114
8. Sutton D, Diamond M, Faucette L et al (2007) GSK923295A, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice [abstract]. In: Proceedings of the 98th annual meeting of the American association of cancer research; Apr 14-18 2007; Los Angeles, CA, Philadelphia (PA) Abstract 1522
9. Hu, Z, Mao, J-H, Huang, G et al (2009) A Systems analysis of mitotic apparatus inhibitors deWnes a response network for breast cancer. 32nd Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. December, Poster Presentation
10. Guidance for Industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); July 2005
11. NCI Common Terminology Criteria for Adverse Events, Version 3, DCTD, NCI, NIH, DHHS, August 9, 2006
12. Simon R, Freilin B, Rubenstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147 (Pubitemid 27337928)
13. Plummer R, Ghielmini M, Calvert P et al (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-18446 given weekly in patients with advanced malignancies. Clin Cancer Res 8:2788-2797 (Pubitemid 35025721)
14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2:205-216 (Pubitemid 30099779)
15. Tas F, Eralp Y, Basaran M et al (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol (CCT) 25(4):371-379 (Pubitemid 34864032)
16. Schwartz GK, Ilson D, Saltz L et al (2001) Phase II study of the cyclin-dependent kinase inhibitor Xavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19(7):1985-1992 (Pubitemid 32702543)
17. Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28:197-208
18. Jackson JR, Patrick DR, Dar MM et al (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107-117 (Pubitemid 46160987)
19. Dupont J, Bienvenu B, Aghajanian C et al (2004) Phase I and pharmacokinetic study of the novel oral cell cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J Clin Oncol 2(16):3366-3374 (Pubitemid 41103695)
20. Johnson B, Sutton D, Fleming R et al (2009) Exploratory methods for assessment of therapeutic exposures and schedules of GSK923295A, a novel mitotic checkpoint inhibitor. 100th AACR Annual Meeting, April 18-22, Denver CO, Poster Presentation, Abstract 5452